NCT01958281View on ClinicalTrials.gov

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 7, 2013

Primary Completion Date

July 18, 2017

Study Completion Date

October 19, 2017

Conditions
HCV Infection
Interventions
DRUG

SOF

Tablet(s) administered orally once daily

DRUG

RBV

200 mg tablet administered orally once daily

DRUG

LDV/SOF

90/400 mg fixed-dose combination (FDC) tablet administered orally once daily

Trial Locations (10)

1142

Grafton

8011

Christchurch

14642

Rochester

33134

Miami

48202

Detroit

60611

Chicago

78215

San Antonio

94115

San Francisco

98104

Seattle

00927

San Juan

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY